{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-336078","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2021-11-22T23:59:59+00:00","discovered_at":"2026-05-14T18:04:14.846624+00:00","generated_at":"2026-06-28T06:17:33.455455+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Tenaya Therapeutics appoints Dr. June Lee to board; Dr. JeenJoo Kang resigns","bullets":["Dr. June Lee appointed as Class III director, term expiring at 2024 annual meeting.","Dr. Lee receives annual cash retainer of $35,000 and stock option grant with ~$320,000 fair value.","Dr. Lee most recently CEO of Esker Therapeutics; previously EVP at MyoKardia advancing cardiomyopathies.","Dr. JeenJoo Kang resigned voluntarily, not due to any disagreement, to focus on CEO role at Appia Bio.","Company highlights transition to clinical-stage and Dr. Lee's relevant development experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-336078","json":"https://secwatch.observer/filing/0001193125-21-336078.json","markdown":"https://secwatch.observer/filing/0001193125-21-336078.md","text":"https://secwatch.observer/filing/0001193125-21-336078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/0001193125-21-336078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/d255712d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T06:17:33.455455+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1293832a27","claim":"JeenJoo Kang resigned as Director at Tenaya Therapeutics, Inc..","evidence_excerpt":"On November 17, 2021, JeenJoo Kang, Ph.D., submitted her resignation as a director of Tenaya Therapeutics, Inc.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/0001193125-21-336078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a3ef063b90","claim":"June Lee was appointed as Director at Tenaya Therapeutics, Inc..","evidence_excerpt":"On November 19, 2021, the Board appointed June Lee, M.D., to serve as a Class III director","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1858848/000119312521336078/0001193125-21-336078-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}